Bal Pharma Ltd Stock Price Today (NSE: BALPHARMA)
Fundamental Score
Bal Pharma Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Bal Pharma Ltd share price today is ₹87.97, down 1.39% on NSE/BSE as of 17 June 2026. Bal Pharma Ltd (BALPHARMA) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹118.87 (Cr). The 52-week high for BALPHARMA share price is ₹106.00 and the 52-week low is ₹60.00. At a P/E ratio of 17.43x, BALPHARMA is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 9.66% and a debt-to-equity ratio of 1.98.
Bal Pharma Ltd Share Price Chart — NSE/BSE Historical Performance
Bal Pharma Ltd share price chart: 27.89% return over the past month. 52-week high ₹106.00, 52-week low ₹60.00.
Bal Pharma Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹84.61 | ₹88.40 | ₹84.46 | ₹87.39 | 14.30K (Cr) | |
| ₹92.30 | ₹92.30 | ₹85.05 | ₹85.90 | 25.90K (Cr) | |
| ₹95.99 | ₹96.97 | ₹88.00 | ₹90.12 | 73.22K (Cr) | |
| ₹93.00 | ₹98.85 | ₹92.50 | ₹96.43 | 1.66L (Cr) | |
| ₹91.00 | ₹94.70 | ₹91.00 | ₹92.32 | 2.05L (Cr) | |
| ₹82.25 | ₹89.45 | ₹82.10 | ₹88.56 | 65.51K (Cr) | |
| ₹84.60 | ₹85.23 | ₹81.11 | ₹82.03 | 9.62K (Cr) | |
| ₹80.25 | ₹87.11 | ₹80.25 | ₹85.13 | 78.28K (Cr) | |
| ₹78.29 | ₹83.00 | ₹78.00 | ₹79.88 | 32.67K (Cr) | |
| ₹78.20 | ₹80.45 | ₹76.94 | ₹78.29 | 10.13K (Cr) |
Bal Pharma Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹92.30 | ₹92.30 | ₹84.46 | ₹87.39 | -5.32% | |
| ₹75.10 | ₹98.85 | ₹74.20 | ₹90.12 | +20.00% | |
| ₹60.20 | ₹81.30 | ₹60.20 | ₹76.21 | +26.59% | |
| ₹72.10 | ₹75.90 | ₹60.00 | ₹60.42 | -16.20% | |
| ₹70.62 | ₹81.50 | ₹66.40 | ₹75.28 | +6.60% | |
| ₹71.50 | ₹78.10 | ₹65.70 | ₹66.76 | -6.63% | |
| ₹76.89 | ₹79.50 | ₹69.00 | ₹73.32 | -4.64% | |
| ₹82.00 | ₹83.96 | ₹73.30 | ₹75.47 | -7.96% | |
| ₹83.49 | ₹90.30 | ₹80.00 | ₹82.45 | -1.25% | |
| ₹88.00 | ₹93.03 | ₹82.46 | ₹82.92 | -5.77% | |
| ₹97.80 | ₹102.99 | ₹84.98 | ₹86.84 | -11.21% | |
| ₹103.00 | ₹104.50 | ₹94.84 | ₹100.05 | -2.86% |
AI Research Briefing
Powered by Gemini · 2026-04-09
Micro-cap pharma with too much debt and negative momentum; stay away.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Bal Pharma's 1% over the past six months and 37.5% over the last year. On March 30, 2026, the stock hit a 52-week low of amidst a stock-specific sell-off. The company confirmed compliance with SEBI dematerialization regulations for Q4 FY26.
CORE STORY (THE REAL GAME)
Bal Pharma is a micro-cap pharma company vulnerable to stock-specific risks, overshadowed by broader industry trends. It's a leveraged play in a sector facing pricing pressure.
- Negative price momentum
- High debt burden
- Micro-cap illiquidity
- Significant debt reduction
- Consistent profitability
- Major order win
- Micro-cap liquidity risk
- High debt-to-equity ratio (1.98)
- Rising interest expenses
FII holdings are negligible (0.23%), indicating a lack of institutional interest.
Indian pharma exports are growing, but pricing pressures remain a headwind.
Free cash flow positive over 5 years (₹34.49 Cr), but recent profitability is questionable.
Near-term outlook is bleak due to debt and negative momentum. A turnaround is possible, but requires significant deleveraging and improved profitability.
Primary Thesis Risk
Debt burden will crush the equity.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Bal Pharma Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Bal Pharma Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of BALPHARMA across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Attractive Valuation (P/E: 17.43 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Consistent Growth Track Record (12.11% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (20.34% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (20.95% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Strong Cash Generation (₹34.49 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (50.86%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
5 factors identified
Below-Average Return on Equity (9.66%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Profit Decline Concern (-31.73%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Elevated Debt Levels (D/E: 1.98)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.
Weak Interest Coverage (1.24x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Limited Institutional Interest (FII+DII: 0.23%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Bal Pharma Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Bal Pharma Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Bal Pharma LtdBal Pharma Ltd...Selected✓ BALPHARMA • 524824 | 41.2/100 | ₹87.97₹88 | ₹118.87₹118.87 | 17.43Average 17.4 Average | 9.66%Poor 9.66% Poor | 10.10%Average 10.10% Average | 1.98Average 2.0 Average | 20.95%Excellent 20.95% Excellent | 12.11%Good 12.11% Good | 1.59% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Bal Pharma Ltd PE Ratio History
Historical price-to-earnings ratio for BALPHARMA — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹4.56 | ₹73.32 | 16.1x |
| FY 2024 | ₹4.94 | ₹122.62 | 24.8x |
| FY 2023 | ₹1.67 | ₹100.05 | 59.9x |
| FY 2022 | ₹3.79 | ₹91.15 | 24.1x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Bal Pharma Ltd Dividend History
Annual cash dividends paid by BALPHARMA — dividend yield 1.59%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹1.91 Cr |
| FY 2024 | ₹1.57 Cr |
| FY 2023 | ₹1.56 Cr |
| FY 2022 | ₹1.48 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Bal Pharma Ltd Quarterly Performance
Latest quarterly metrics for BALPHARMA — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
0.45%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-31.73%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
12.11%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
20.95%
Compounded annual net profit growth over 5 years
Bal Pharma Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for BALPHARMA — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Bal Pharma Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Bal Pharma Ltd (BALPHARMA) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Bal Pharma Ltd
About BALPHARMA (Bal Pharma Ltd)
Bal Pharma Ltd is a dynamic pharmaceutical entity focused on the development, manufacturing, and global distribution of a diverse range of pharmaceutical products. The company dist...inguishes itself through its dedication to innovation and its commitment to providing accessible healthcare solutions across multiple therapeutic areas. Bal Pharma operates with a multifaceted approach, encompassing the production of both finished formulations and active pharmaceutical ingredients (APIs), ensuring a vertically integrated supply chain and greater control over product quality. With a strong presence in both domestic and international markets, Bal Pharma seeks to address unmet medical needs and improve patient outcomes through the consistent delivery of high-quality, affordable medications. Bal Pharma's product portfolio caters to a wide spectrum of medical conditions, reflecting its understanding of evolving healthcare demands. Their offerings include prescription medications targeting various ailments, generic alternatives providing cost-effective treatment options, over-the-counter (OTC) products for self-care, and essential intravenous infusion products. The company also specializes in bulk drug manufacturing, supplying vital ingredients to other pharmaceutical companies. Through strategic brand development, Bal Pharma offers specialized products focused on key therapeutic areas such as anti-infectives, pain relief, respiratory health, and women's health, with established brands like Aziwin and Monogesic Plus Gel. Moreover, Bal Pharma is actively engaged in addressing the growing global prevalence of diabetes. The company's diabetic care product range reflects its commitment to improving the lives of individuals managing this chronic condition. By focusing on research and development, Bal Pharma continuously strives to introduce innovative and effective pharmaceutical solutions that enhance treatment outcomes and improve the overall quality of life for patients. Ultimately, Bal Pharma aims to be a reliable partner in healthcare, providing a comprehensive range of pharmaceutical products that meet the diverse needs of patients and healthcare professionals alike.
Company Details
Key Leadership
Corporate Events
BALPHARMA Share Price: Frequently Asked Questions
What is the current share price of Bal Pharma Ltd?
Bal Pharma Ltd (BALPHARMA) trades at ₹87.97 on NSE and BSE. Market cap ₹118.87 (Cr). Educational data only.
What is the P/E ratio of Bal Pharma Ltd?
Bal Pharma Ltd has a P/E of 17.43x vs industry average 31.77x.
What is the Bull Run score for Bal Pharma Ltd?
Bal Pharma Ltd has a Bull Run score of 41.2/100 based on 25+ financial parameters.
Does Bal Pharma Ltd pay dividends?
Bal Pharma Ltd has a dividend yield of 1.59%. Past dividends don't guarantee future payments.
What is the ROE of Bal Pharma Ltd?
Bal Pharma Ltd has ROE of 9.66%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Bal Pharma Ltd?
Bal Pharma Ltd has debt-to-equity of 1.98.
Is Bal Pharma Ltd a good investment?
Bull Run gives Bal Pharma Ltd a score of 41.2/100. This is not investment advice — consult a SEBI-registered advisor.